| Literature DB >> 35349660 |
Melody Kasher1, Frances M K Williams2, Maxim B Freidin2, Ida Malkin1, Stacey S Cherny1,3, Gregory Livshits1,2,4.
Abstract
Rheumatoid arthritis (RA) and osteoporosis (OP) are two comorbid complex inflammatory conditions with evidence of shared genetic background and causal relationships. We aimed to clarify the genetic architecture underlying RA and various OP phenotypes while additionally considering an inflammatory component, C-reactive protein (CRP). Genome-wide association study summary statistics were acquired from the GEnetic Factors for OSteoporosis Consortium, Cohorts for Heart and Aging Research Consortium and UK Biobank. Mendelian randomization (MR) was used to detect the presence of causal relationships. Colocalization analysis was performed to determine shared genetic variants between CRP and OP phenotypes. Analysis of pleiotropy between traits owing to shared causal single nucleotide polymorphisms (SNPs) was performed using PL eiotropic A nalysis under CO mposite null hypothesis (PLACO). MR analysis was suggestive of horizontal pleiotropy between RA and OP traits. RA was a significant causal risk factor for CRP (β = 0.027, 95% confidence interval = 0.016-0.038). There was no evidence of CRP→OP causal relationship, but horizontal pleiotropy was apparent. Colocalization established shared genomic regions between CRP and OP, including GCKR and SERPINA1 genes. Pleiotropy arising from shared causal SNPs revealed through the colocalization analysis was all confirmed by PLACO. These genes were found to be involved in the same molecular function 'protein binding' (GO:0005515) associated with RA, OP and CRP. We identified three major components explaining the epidemiological relationship among RA, OP and inflammation: (1) Pleiotropy explains a portion of the shared genetic relationship between RA and OP, albeit polygenically; (2) RA contributes to CRP elevation and (3) CRP, which is influenced by RA, demonstrated pleiotropy with OP.Entities:
Mesh:
Substances:
Year: 2022 PMID: 35349660 PMCID: PMC9402243 DOI: 10.1093/hmg/ddac061
Source DB: PubMed Journal: Hum Mol Genet ISSN: 0964-6906 Impact factor: 5.121
Predictors of RA in ELSA
| RA-associated covariates | |||||||
|---|---|---|---|---|---|---|---|
| Variables | B | SE |
|
| OR | Lower 95% CI | Upper 95% CI |
| Intercept | −2.9581 | 0.0659 | −44.9 | <2.2E−16 | 0.0519 | 0.0455 | 0.0589 |
| Age | 0.2818 | 0.0650 | 4.3 | 1.47E−05 | 1.3254 | 1.1666 | 1.5056 |
| BMI | 0.3585 | 0.0534 | 6.7 | 2.01E−11 | 1.4311 | 1.2874 | 1.5877 |
| hsCRP | 0.1144 | 0.0407 | 2.8 | 4.95E−03 | 1.1211 | 1.0271 | 1.2082 |
| OP | 0.5084 | 0.1848 | 2.8 | 5.94E−03 | 1.6627 | 1.1417 | 2.3604 |
Multiple logistic regression on the ELSA dataset (Wave 6) where RA served as the dependent variable and OP served as an independent covariate in addition to age, BMI and hsCRP. The study sample is composed of 10 183 individuals in total of which 629 were diagnosed with RA and 786 were diagnosed as OP cases; hsCRP levels were measured in 6125 individuals. OR was estimated per SD of the phenotype variation. The independent variables initially included in the analysis were age, sex, BMI, hsCRP, fibrinogen levels, WBC count and OP. Only statistically significant results are reported in the table.
MR of RA as exposure and OP or CRP as outcome using the MRE approach
| Exposure→outcome | Number of IVs | MRE estimate | 95% CI of MRE | MRE | MR intercept | Heterogeneity |
|
|---|---|---|---|---|---|---|---|
| RA→UKB OP | 43 | 0.000 | 0.000, 0.001 | 0.603 | 0.001 | 0.9818 | 99.5 |
| RA→OP fracture | 34 | 0.014 | −0.018, 0.037 | 0.495 | <0.001 | 0.9483 | 99.2 |
| RA→total body BMD | 38 | −0.005 | −0.022, 0.012 | 0.562 | 0.002 | 0.8051 | 99.1 |
| RA→spine BMD | 43 | 0.006 | −0.022, 0.034 | 0.680 | 0.001 | 0.9994 | 98.4 |
| RA→hip BMD | 41 | −0.036 | −0.063, −0.008 | 0.011 | 0.295 |
| 96.9 |
| RA→arm BMD | 38 | −0.021 | −0.072, 0.030 | 0.418 | 0.006 | 0.9993 | 99.0 |
| RA→UKB heel BMD | 38 | −0.006 | −0.015, 0.003 | 0.200 | <0.001 | 0.5505 | 99.1 |
| RA→CRP | 41 | 0.027 | 0.016, 0.038 | <0.001 | 0.132 | 1.000 | 99.3 |
MRE results where RA served as the exposure variable with OP or CRP as the outcome variables in separate univariate analyses. The SNPs selected as instrumental variables had P ≤ 5E−08.
MRE results where CRP was the exposure variable and OP served as the outcome variable in separate univariate analyses
| Exposure→outcome | Number of IVs | MRE estimate | 95% CI of MRE β value | MRE | MR intercept | Heterogeneity |
|
|---|---|---|---|---|---|---|---|
| CRP→UKB OP | 32 | −0.001 | −0.003, 0.002 | 0.672 | 0.002 | 0.9676 | 98.7 |
| CRP→OP fracture | 25 | −0.013 | −0.116, 0.089 | 0.799 | 0.002 | 0.8983 | 98.1 |
| CRP→total body BMD | 44 | −0.028 | −0.080, 0.024 | 0.287 | 0.002 | 0.9465 | 98.3 |
| CRP→spine BMD | 40 | −0.032 | −0.110, 0.047 | 0.427 | 0.021 | 0.4210 | 98.8 |
| CRP→hip BMD | 41 | 0.006 | −0.084, 0.095 | 0.896 | <0.001 | 0.8518 | 98.0 |
| CRP→arm BMD | 37 | −0.013 | −0.187, 0.160 | 0.880 | 0.006 | 0.9964 | 98.0 |
| CRP→UKB heel BMD | 40 | 0.005 | −0.021, 0.031 | 0.703 | <0.001 | 0.9609 | 98.6 |
CRP served as the exposure variable and various OP phenotypes act as the outcome variables in separate univariate analyses. The SNPs selected as IVs had P ≤ 5E−08.
Colocalization and gene-set enrichment for OP variables and CRP in H4
| Chromosome and region | OP variable colocalized with CRP | Gene and (SNP) | Function | OP variable | CRP | PP. H4 (%) |
|---|---|---|---|---|---|---|
| Chr 1, 65 041 704–66 939 404 | UKB heel QUS BMD |
| Intergenic | 4.91E−05 | 1.35E−134 | 79.3 |
| Chr 2, 10 133–1 781 022 | UKB heel QUS BMD |
| Intergenic | 4.86E−07 | 3.42E−08 | 80.9 |
| Chr 2, 26 894 985–28 598 777 | GEFOS total body BMD |
| Exonic, non-synonymous SNV, exon14 | 7.48E−08 | 5.44E−61 | 99.3 |
| Chr 9, 135 298 842–137 041 122 | UKB heel QUS BMD |
| ncRNA_intronic | 1.71E−10 | 6.33E−09 | 90.0 |
| Chr 14, 94 325 285–95 750 867 | UKB OP |
| Exonic, non-synonymous SNV, exon5 | 2.25E−05 | 5.47E−10 | 84.7 |
| Chr 14, 94 325 285–95 750 867 | UKB OP |
| Intergenic | 1.43E−05 | 2.20E−10 | 84.7 |
| Chr 14, 94 325 285–95 750 867 | GEFOS total body BMD |
| Exonic, non-synonymous SNV, exon5 | 3.65E−04 | 5.47E−10 | 84.4 |
| Chr 14, 94 325 285–95 750 867 | GEFOS total body BMD |
| Intergenic | 4.27E−04 | 2.20E−10 | 84.4 |
| Chr 14, 94 325 285–95 750 867 | GEFOS spine BMD |
| Intergenic | 3.66E−04 | 2.20E−10 | 88.0 |
| Chr 22, 37 570 269–39 307 894 | UKB heel QUS BMD |
| Exonic, synonymous SNV, exon16 | 4.31E−09 | 2.97E−09 | 76.4 |
| Chr 22, 37 570 269–39 307 894 | UKB heel QUS BMD |
| Intronic | 6.59E−09 | 4.75E−10 | 76.4 |
Results of common colocalizing genetic variants and their respective genes seen between OP phenotypes and CRP as determined by high PP of H4 (PP.H4 ≥ 75%) arising from commonly shared SNPs.
Figure 1The diagram represents the three MR assumptions: (1) the IVs or genetic variants (SNPs of interest) are associated with the exposure phenotype only, (2) the exposure and outcome do not share a common cause (confounders) and (3) the IVs influence the outcome only through the exposure.